News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Zeltia Group Shares Soar After Cancer Drug Approval
July 20, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, July 20 (Reuters) - Shares in Spanish drug company Zeltia (ZEL.MC: Quote, Profile, Research) soared on Friday after its cancer treatment Yondelis was recommended for approval in Europe, its first medicine to make its way to the market.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Policy
FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking
July 17, 2026
·
3 min read
·
Tristan Manalac
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
·
3 min read
·
John Potter
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
July 16, 2026
·
2 min read
·
Gabrielle Masson
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
July 15, 2026
·
1 min read
·
Jef Akst
